- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04819347
Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
The Phase 2, Two Arms, One Site, Safety and Antiviral Activity of Combination Therapy With Albuvirtide and 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection After Analytical Treatment Interruption
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is an open-label, one site study, in which a total of 24 HIV-1 subjects who are virologically suppressed and stable on daily oral combination antiretroviral therapy will be enrolled.
All eligible patients will be switched from daily oral combination antiretroviral regimen to treatment of ABT and 3BNC117 for 14 weeks. There is a two-week overlap of the baseline oral antiretroviral therapy and the ABT-3BNC117 combination regimen at the beginning of the study treatment, and then the oral ART will be interrupted.
The patients will be monitored for viral rebound every two or four weeks following initiation of ABT-3BNC117 combination and will re-initiate an oral antiretroviral regimen if virological rebound is confirmed with plasma HIV-1 RNA levels above 200 copies/ml on two consecutive test.
Pharmacokinetics of ABT and 3BNC117 will be assessed in this study.
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Cheng Yao
- Correo electrónico: yaocheng@frontierbiotech.com
Copia de seguridad de contactos de estudio
- Nombre: Xingxiang Xu
- Número de teléfono: 025-69648410
- Correo electrónico: xxxu@frontierbiotech.com
Ubicaciones de estudio
-
-
-
Beijing, Porcelana
- Peking Union Medical College Hospital
-
Contacto:
- Taisheng Li, M.D.
- Correo electrónico: litsh@263.net
-
Investigador principal:
- Taisheng Li, M.D.
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Males and females, age ≥18 years
For cohort 1: HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) within 6 months of primary HIV infection (PHI), having the document evidence of initial diagnosis of HIV-1 infection and initiation of ART therapy within 6 months of PHI.
For cohort 2: Chronically HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) after 6 months of primary HIV infection (PHI), having the document evidence of initial diagnosis of HIV-1 infection and initiation of ART therapy after 6 months of PHI.
- Plasma HIV-1 RNA <50 copies/mL for at least 12 months prior to Screening Visit. An exception for a recorded HIV-1 RNA "blip" (e.g., transient HIV-1 RNA >50 copies/mL) can be considered.
- Plasma HIV-1 RNA <20 copies/mL at Screening Visit.
- CD4 cell count >500 cells/µL.
Laboratory values at Screening of:
- Absolute neutrophil count (ANC) ≥0.75×10∧9/L;
- Hemoglobin (Hb) ≥105 g/L (male) or ≥95 g/L (female);
- Platelets ≥75×10∧9/L;
- Serum alanine transaminase (SGPT/ALT) < 2 x upper limit of normal (ULN)
- Serum aspartate transaminase (SGOT/AST) < 2 x ULN
- Bilirubin (total) <2.5 x ULN unless Gilbert's disease is present or subject is receiving atazanavir in the absence of other evidence of significant liver disease
- Creatinine ≤1.5 x ULN
- Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered not clinically significant by the Principal Investigator.
- Both male and female patients and their partners of childbearing potential must agree to use accepted methods of contraception.
- Females of childbearing potential must have a negative serum pregnancy test at Screening visit and negative urine pregnancy test prior to receiving the first dose of study drug.
- Subjects who have two or more potential alternative antiretroviral treatment regimens.
- Willing and able to participate in all aspects of the study, including use of IV medication, completion of evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent.
Exclusion Criteria:
- Any active infection or malignancy requiring acute therapy.
- Hepatitis B infection as manifest by the presence of Hepatitis B surface antigen (HBsAg).
- Hepatitis C infection as manifest by positive anti-HCV antibody and positive HCV RNA assay at the time of screening.
- Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study
- Unexplained fever or clinically significant illness within 1 week prior to the first study dose
- Any vaccination within 2 weeks prior to the first study dose.
- Subjects BMI<20 or >27 kg/m∧2 [BMI=weight/height∧2].
- History of Bleeding Disorder or patients on anti-coagulant therapy
- Participation in an experimental drug trial(s) within 30 days of the Screening Visit
- Any known allergy or antibodies to the study drug or excipients
Treatment with any of the following:
- Radiation or cytotoxic chemotherapy with 30 days prior to the screening visit
- Receipt of any fusion inhibitor and monoclonal antibody therapy of any kind in the past.
- Immunosuppressants within 60 days prior to the Screening Visit
- Immunomodulating agents (e.g., interleukins, interferons), hydroxyurea, or foscarnet within 60 days prior to the screening visit
- Oral or parenteral corticosteroids within 30 days prior to the Screening Visit. Subjects on chronic steroid therapy > 5 mg/day will be excluded with the following exception:
- Subjects on inhaled, nasal, or topical steroids will not be excluded
- Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Early treatment of infection
HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) within 6 months of primary HIV infection (PHI), and had plasma HIV-1 RNA <50 copies/mL for at least 12 months. Albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks IV infusion for a total of 14 weeks. |
Inhibidor de la fusión del VIH-1 de acción prolongada (péptido modificado químicamente que se dirige a la gp41 del VIH-1)
Otros nombres:
Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120.
|
Experimental: Chronic period of infection treatment
Chronically HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) after 6 months of primary HIV infection (PHI), and had plasma HIV-1 RNA <50 copies/mL for at least 12 months. Albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks IV infusion for a total of 14 weeks. |
Inhibidor de la fusión del VIH-1 de acción prolongada (péptido modificado químicamente que se dirige a la gp41 del VIH-1)
Otros nombres:
Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Proportion of participants (with sustained viral suppression at week 14) with HIV-1 RNA < 50 copies/mL at Week 26 (24 weeks after ATI)
Periodo de tiempo: Week 26
|
Proportion of participants with HIV-1 RNA < 50 copies/mL at Week 26.
|
Week 26
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Mean time to virologic rebound (HIV-1 RNA≥200 copies/mL) after ATI
Periodo de tiempo: up to 48 weeks
|
Mean time to virologic rebound
|
up to 48 weeks
|
Proportion of participants without experiencing virologic rebound (HIV-1 RNA<200 copies/mL) at Week 26 (24 weeks after ATI).
Periodo de tiempo: Week 26
|
Proportion of participants without experiencing virologic rebound
|
Week 26
|
Proportion of participants with HIV-1 RNA < 50 copies/mL at Week 26 (24 weeks after ATI).
Periodo de tiempo: Week 26
|
Proportion of participants with HIV-1 RNA < 50 copies/mL at Week 26
|
Week 26
|
Mean change in CD4 cell count after ATI
Periodo de tiempo: up to 48 weeks
|
Mean change in CD4 cell count
|
up to 48 weeks
|
Mean change in CD4/CD8 ration after ATI
Periodo de tiempo: up to 48weeks
|
Mean change in CD4/CD8 ration
|
up to 48weeks
|
Frequency of emergence of new resistance mutations after virologic rebound
Periodo de tiempo: up to 48 weeks
|
Frequency of emergence of new resistance mutations
|
up to 48 weeks
|
Mean time to achieving HIV-1 RNA < 50 copies/mL after experiencing virologic rebound
Periodo de tiempo: up to 48 weeks
|
Mean time to achieving HIV-1 RNA < 50 copies/mL after experiencing virologic rebound
|
up to 48 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Cheng Yao, Frontier Biotechnologies Inc.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Anticipado)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Síndromes de deficiencia inmunológica
- Enfermedades del sistema inmunológico
- Enfermedades de virus lentos
- Infecciones por VIH
- Infecciones
- Síndrome de inmunodeficiencia adquirida
Otros números de identificación del estudio
- ABT-3BNC117_202
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre VIH/SIDA
-
Icahn School of Medicine at Mount SinaiIRRASReclutamientoHemorragia Intraventricular (HIV)Estados Unidos
-
Yale UniversityTerminadoPrecocidad | Recién nacidos de muy bajo peso al nacer | Hemorragia Intraventricular (HIV) | Sangrado en el cerebroEstados Unidos
-
China Medical University HospitalDesconocidoDisplasia broncopulmonar | Bebés extremadamente prematuros | TLP grave que las terapias convencionales han fallado | Sin anomalías congénitas graves | no Hiv Severa Ni FPV QuísticaTaiwán